Menstruation recovery after chemotherapy and luteinizing hormone-releasing hormone agonist plus tamoxifen therapy for premenopausal patients with breast cancer

By Sakurai Kenichi   Matsuo Sadanori   Enomoto Katsuhisa   Amano Sadao   Shiono Motomi  

Surgery Today, Vol. 41, Iss. 1, 2011-01 ,pp. : 48-53

Springer Publishing Company

Access to resources Recommend Favorite

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer

By Schellhammer P.   Sharifi R.   Block N.   Soloway M.   Venner P.   Patterson A.L.   Sarosdy M.   Vogelzang N.   Jones J.   Kolvenbag G.  

Urology, Vol. 45, Iss. 5, 1995-05 ,pp. : 745-752

Elsevier

Access to resources Recommend Favorite

Protection of the germinal epithelium in the rat from the cytotoxic effects of chemotherapy by a luteinizing hormone-releasing hormone agonist and antiandrogen therapy

By Cespedes R.D.   Peretsman S.J.   Thompson I.M.   Jackson C.  

Urology, Vol. 46, Iss. 5, 1995-11 ,pp. : 688-691

Elsevier

Access to resources Recommend Favorite

Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer

By Kobayashi Takashi   Nishizawa Koji   Mitsumori Kenji  

Scandinavian Journal of Urology and Nephrology, Vol. 40, Iss. 3, 2006-05 ,pp. : 198-203

Informa Healthcare

Access to resources Recommend Favorite

Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer - implications for dosing schedule and neoadjuvant study consideration

By Hall M.C.   Fritzsch R.J.   Sagalowsky A.I.   Ahrens A.   Petty B.   Roehrborn C.G.  

Urology, Vol. 53, Iss. 5, 1999-05 ,pp. : 898-902

Elsevier

Access to resources Recommend Favorite